Dosage form for administration of dehydroepiandrosterone
Patent 4978532 Issued on December 18, 1990. Estimated Expiration Date: 
August 11, 2009. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
August 11, 2009. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesPharmaceutical preparations containing cyclodextrin derivatives Transdermal absorption dosage unit for estradiol and other estrogenic steroids and process for administration Pharmaceutical vehicles for exhancing penetration and retention in the skin Patent #: 4895727 InventorAssigneeApplicationNo. 392728 filed on 08/11/1989US Classes:424/448, Pressure sensitive adhesive means424/449, Transdermal or percutaneous424/486, Synthetic polymer514/178Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring systemExaminersPrimary: Cashion, Merrell C. Jr.Assistant: Phelan, D. Gabrielle Attorney, Agent or FirmInternational ClassA61F 013/00AbstractA dosage form for the delivery of dehydroepiandrosterone (DHEA) to a patient is described. The dosage form has an adhesive matrix containing a pressure-sensitive medical-grade silicone adhesive, DHEA, and a permeation enhancer for DHEA. The permeation enhancer is an aromatic or aliphatic carbocyclic compound with pendant hydroxyl groups. | |
